Clinical and Radiographic Predictors of Great Vessel Resection or Reconstruction During Retroperitoneal Lymph Node Dissection for Testicular Cancer.


Journal

Urology
ISSN: 1527-9995
Titre abrégé: Urology
Pays: United States
ID NLM: 0366151

Informations de publication

Date de publication:
01 2019
Historique:
received: 29 05 2018
revised: 17 08 2018
accepted: 22 08 2018
pubmed: 5 9 2018
medline: 16 5 2019
entrez: 5 9 2018
Statut: ppublish

Résumé

To evaluate whether specific clinical or radiographic factors predict inferior vena cava (IVC) or abdominal aortic (AA) resection or reconstruction (RoR) at the time of postchemotherapy retroperitoneal lymph node dissection (RPLND) for germ cell tumors of the testicle. Two hundred seventy-seven patients undergoing postchemotherapy RPLND at two institutions between 2005 and 2015 were identified. Preoperative imaging was reviewed with radiologists blinded to operative details. Univariable and multivariable logistic regressions were performed, and a model was created to predict the need for great vessel RoR using radiographic and clinical factors. Of 97 patients with preoperative imaging and clinical data available, 16 (17%) underwent RoR at RPLND. On univariable analysis dominant mass size, degree of circumferential vessel involvement, and vessel deformity were associated with RoR (all P <.05). No patients with clinical stage IIA or IIB disease at diagnosis required RoR. In the multivariable model, mass involvement of the IVC >135° (odds ratio 65.5, 7.8-548, P <.01) and involvement of the AA >330° (odds ratio 29.0, 3.44-245, P <.01) were predictive for RoR. These thresholds yielded a PPV of 48% and 50% and a NPV of 92% and 97% for IVC and AA RoR, respectively. Degree of circumferential involvement of the great vessels is an independent predictor for resection or reconstruction of the IVC or AA at postchemotherapy RPLND. Patients at high risk of great vessel reconstruction should be informed accordingly and have the proper teams available for complex vascular reconstruction.

Identifiants

pubmed: 30179635
pii: S0090-4295(18)30916-6
doi: 10.1016/j.urology.2018.08.028
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

186-190

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2018. Published by Elsevier Inc.

Auteurs

Scott C Johnson (SC)

University of Chicago, Department of Surgery, Section of Urology, Chicago, IL. Electronic address: charlesjohnsonscott@gmail.com.

Zachary L Smith (ZL)

University of Chicago, Department of Surgery, Section of Urology, Chicago, IL.

Charles Nottingham (C)

University of Chicago, Department of Surgery, Section of Urology, Chicago, IL.

Zeyad R Schwen (ZR)

James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD.

Stephen Thomas (S)

University of Chicago, Department of Surgery, Section of Urology, Chicago, IL.

Elliot K Fishman (EK)

James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD.

Nam Ju Lee (NJ)

James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD.

Philip M Pierorazio (PM)

James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD.

Scott E Eggener (SE)

University of Chicago, Department of Surgery, Section of Urology, Chicago, IL.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH